Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Langerhans Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Langerhans Cell. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005051-20 Sponsor Protocol Number: HISTIOGEN Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Determination Of Molecular Status And Benefit Of Use Fludeoxyglucose (18F-FDG) In PET/CT imagining In Juvenile Patients With Histiocytosis
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005053-25 Sponsor Protocol Number: TRAM Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005052-37 Sponsor Protocol Number: BRAVO Start Date*: 2021-04-01
    Sponsor Name:Institute of Mother and Child
    Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005806-38 Sponsor Protocol Number: NO21884 Start Date*: 2009-10-23
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with a...
    Medical condition: PIb: solid malignancy that is metastatic or unresectable PII: C 1: Advanced metastatic renal cell carcinoma C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancre...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050076 Metastatic renal carcinoma LLT
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052399 Neuroendocrine tumour LLT
    9.1 10026664 Malignant pancreatic islet neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003300-31 Sponsor Protocol Number: 20159460(c) Start Date*: 2017-06-13
    Sponsor Name:Hellenic Society for the Study of Bone Metabolism
    Full Title: Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial.
    Medical condition: Langerhans Cell Histiocytosis (LCH) is a rare disease of unknown etiology with variable clinical course exhibiting both neoplastic and inflammatory features. It is characterized by the accumulatio...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001699-20 Sponsor Protocol Number: 042011 Start Date*: 2012-05-18
    Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
    Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing) BE (Ongoing) NL (Ongoing) DK (Ongoing) NO (Ongoing) IE (Ongoing) IT (Ongoing) SE (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002388-15 Sponsor Protocol Number: LCH-III Start Date*: 2005-03-10
    Sponsor Name:AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI
    Full Title: LCH-III Treatment Protocol of the Third International Study for LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell Histiocytosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10020118 Histiocytoses HLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000106-37 Sponsor Protocol Number: 37.07.-92906 Start Date*: 2008-08-28
    Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
    Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
    Medical condition: Psoriasis vulgaris (Plaque-Typ)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014912-36 Sponsor Protocol Number: SIM001 Start Date*: 2009-09-22
    Sponsor Name:Karolinska Institutet
    Full Title: Behandling vid Langerhans cellhistiocytos (LCH)
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002392-40 Sponsor Protocol Number: LCH-A1 Start Date*: 2007-10-05
    Sponsor Name:VU University Medical Center
    Full Title: LCH-A1, first international study for Langerhans Cell Histiocytosis in adults
    Medical condition: Langerhans Cell Histiocytosis in adults with single system disease with multifocal bonelesions or with lesions in the craniofacial bones with brain extension or in the vertebral bones with intrasp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020117 Histiocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003936-21 Sponsor Protocol Number: TD-212-2308 Start Date*: 2015-09-14
    Sponsor Name:Hôpital de Jolimont
    Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE...
    Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003568-38 Sponsor Protocol Number: LCH-IV-G-2016 Start Date*: 2017-11-14
    Sponsor Name:Johann Wolfgang Goethe-University Frankfurt am Main
    Full Title: German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV
    Medical condition: Langerhans cell Histiocytosis (LCH)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000425-45 Sponsor Protocol Number: Start Date*: 2012-07-03
    Sponsor Name:
    Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.
    Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055008 Gastric sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000888-41 Sponsor Protocol Number: MetNET1trial Start Date*: 2014-06-05
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori
    Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono...
    Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006126-10 Sponsor Protocol Number: Efalizumab in CTCL Start Date*: 2008-11-27
    Sponsor Name:Charité - University Hospital Berlin
    Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma
    Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 23:32:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA